To earn CME related to this news article, click here. February 17, 2009 — Adalimumab therapy is more effective than placebo for inducing fistula healing in patients with active Crohn's disease (CD), ...

Please provide your email address to receive an email when new articles are posted on . Drainage resolution was achieved in 44.7% of upadacitinib-treated patients at the end of induction and up to ...

Guselkumab demonstrated significantly higher rates of combined fistula remission at 24 weeks compared with placebo among ...

Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an ...

NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its StemSmart cell therapy, with all patients showing improvement.

A 65 year old male with an extensive operative history for Crohn's disease, including 4 laparotomies with small bowel resections to ameliorate small bowel obstructions presented to us. His first ...